Minimally Invasive Surgery for Spontaneous Supratentorial Intracerebral Hemorrhage
A Meta-Analysis of Randomized Controlled Trials

Xinyu Zhou, MD; Jianjun Chen, MD; Qi Li, PhD; Gaoping Ren, MD; Guoen Yao, PhD; Ming Liu, MD; Qiang Dong, PhD; Jing Guo, MD; Leilei Li, PhD; Jing Guo, MD; Peng Xie, MD

Background and Purpose—There has been a nonstandard surgical procedure and extensive international controversy in minimally invasive surgery (MIS) for the management of spontaneous supratentorial intracerebral hemorrhage. This meta-analysis assessed the effectiveness of MIS as compared with other treatment options, including conservative medical treatment and conventional craniotomy, in patients with supratentorial intracerebral hemorrhage.

Methods—PubMed, Embase, Cochrane Controlled Trials Register (CCTR), Web of Science, European Association for Grey Literature Exploitation (EAGLE), National Technical Information Service (NTIS), Current Controlled Trials, Clinical Trials, International Clinical Trials Registry, Internet Stroke Center, Chinese Biomedical Literature Database (CBM), Chinese National Knowledge Infrastructure (CNKI) (last searched December 2011) were searched. Randomized controlled trials on MIS in patients with computed tomography-confirmed supratentorial intracerebral hemorrhage were included. We excluded low-quality randomized controlled trials. The death or dependence at the end of follow-up was defined as the primary outcome, and the death at the end of follow-up was defined as the secondary outcome.

Results—The 313 randomized controlled trials met the included criteria. We only analyzed 12 high-quality randomized controlled trials involving 1955 patients. The quality of the included trials was consistently high. OR of the primary outcome and secondary outcome of MIS both showed significant reductions (OR, 0.54, P<0.00001; OR, 0.53, P<0.00001).

Conclusions—Patients with supratentorial intracerebral hemorrhage may benefit more from MIS than other treatment options. The most likely candidates to benefit from MIS are both sexes, age of 30 to 80 years with superficial hematoma, Glasgow Coma Scale score of ≥9, hematoma volume between 25 and 40 mL, and within 72 hours after onset of symptoms. Our study could help select appropriate patients for MIS and guide clinicians to optimize treatment strategies in supratentorial intracerebral hemorrhage. (Stroke. 2012;43:00-00.)

Key Words: acute stroke □ cerebrovascular accident □ intracerebral hemorrhage □ meta-analysis □ minimally invasive surgical procedures

Spontaneous intracerebral hemorrhage is a common subtype of stroke with high incidence rates and mortality worldwide of which over two thirds of deaths are in developing countries, where are >100,000 deaths and approximately 300,000 disabilities annually in China.1-3 Supratentorial spontaneous intracerebral hemorrhage (SICH), which accounts for 78% to 88% of intracerebral hemorrhages, is primarily caused by spontaneous rupture of small vessels in individuals with arterial hypertension.4 Since the first successful surgery of SICH in 1908, many scholars have done research on the management of SICH.5,6 The choice between surgery and conservative treatment has still been the focus of international controversy.7,8 A previous systematic review, published in 2007, reported that surgery could possibly benefit more in patients with SICH compared with conservative medical treatment.9 However, its evidence was not very robust and some recent randomized controlled trials (RCTs) appeared to provide novel views on this issue.10-12

In the last 20 years, minimally invasive surgery (MIS) techniques, including endoscopic surgery and stereotactic aspiration, have been widely used in the treatment of patients with SICH.13 In China, there are >150,000 patients with...
SICH for MIS treatment every year. Advantages of MIS for treatment of SICH are not only suitable for minimal surgical trauma, but also associated with a shorter operative time and the potential to use local anesthesia. A high-quality trial reported significantly improved functional outcomes in patients with SICH treated with minimally invasive craniopuncture, a modified procedure of stereotactic aspiration form China, compared with conservative medical treatment. However, some scholars believed that MIS could not completely remove hematomas compared with conventional craniotomy because of reducing surgical exposure. There is a potential risk for rebleeding related to the use of fibrinolitics and an increased risk of infection related to prolonged use of indwelling catheters. The results of 2 studies demonstrated that the outcome of endoscopic evacuation and stereotactic aspiration were not better than those of conservative medical treatment. This controversy challenges clinicians and scholars to engage in innovative thinking of selecting the appropriate treatment strategies for SICH.

In our previous studies, we have investigated the epidemiology, prevention, and management strategies for stroke in China. In addition, we also participated in a prospective randomized controlled study, which compared the effectiveness of minimally invasive stereotactic puncture therapy versus conventional craniotomy in SICH. Recently, several large RCTs on the management of SICH have been published, and there is an urgent need for additional systematic review to assist clinicians in establishing an optimal treatment strategy.

Methods

Search Strategy and Selection Criteria

We searched relevant international databases (PubMed, Embase, Cochrane Controlled Trials Register [CTR]), and Web of Science). 2 gray databases (European Association for Grey Literature Exploitation [EAGLE] and National Technical Information Service [NTIS]), 2 Chinese databases (Chinese Biomedical Literature Database-disc and Chinese National Knowledge Infrastructure [CNKI]), and relevant web sites (Current Controlled Trials, Clinical Trials, International Clinical Trials Registry, and Internet Stroke Center) up to December 2011 with different combinations of the following key words: "intracerebral" or "intracranial" or "cerebral" or "brain" or "putaminal" or "infratentorial" or "basal ganglia hemorrhage" or "thamic" or "b(h)emor(hagic stroke" and "b(h)emorrhage" or "b(h)ematoma" and "minimally invasive" or "minimal surgical procedures" or "endoscopy(ic)" or "stereotaxy(ic)" or "aspiration" or "keyhole" or "craniopuncture." We obtained additional relevant articles by scanning conference summaries and reference lists of articles identified in the initial searches and contacted authors to obtain additional information for relevant trials.

Inclusion criteria were as follows: (1) CT-confirmed diagnosis of SICH; and (2) RCTs comparing MIS (endoscopic evacuation or stereotactic aspiration) with other treatment options, including routine medical treatment or craniotomy. Exclusion criteria were as follows: (1) hemorrhage caused by brain injury, brain tumor bleeding, coagulopathy, intracranial aneurysm, cerebral arteriovenous malformation, subdural hemorrhage, epidural hemorrhage, subarachnoid hemorrhage, or pituitary apoplexy; (2) infratentorial intracerebral hemorrhage, including cerebellar hemorrhage or brain stem hemorrhage; and (3) a total study quality assessment score of <2. Patients with infratentorial hematomas were not included because treatment seems to be associated with an unpredictable and high-risk outcome and there has been a consensus among experts.

The study quality assessment referred to the Cochrane criteria: (1) random sequence generation ("yes"=2, "unclear"=1, and "no"=0); (2) allocation concealment ("yes"=2, "unclear"=1, and "no"=0); (3) blinding of outcome assessment ("yes"=2, "unclear"=1, and "no"=0); and (4) incomplete outcome data reported ("yes"=1 and "no"=0). We viewed studies with a total score of <2 as low-quality literature.

Data Extraction

Two review authors (J.J.C., X.Y.Z.) independently identified the articles by inclusion and exclusion criteria, assessed the quality of the articles, and completed a standardized data extraction form. Any disagreements were resolved by discussion.

We used the composite outcome of death or dependence in activities of daily living at the end of follow-up as the primary outcome. Death at the end of follow-up was considered as the secondary outcome. These were chosen because clinicians not only want information on patient survival, but also pay more attention to survivors whether they are functionally dependent or independent. In this review, patients’ dependence or independence was classified by certain activities of daily living scales. The cutoff points of dependence in the activities of daily living scales were a Barthel Index score of ≤60, modified Rankin Scale score of ≥2, and a Glasgow Outcome Scale score of ≥3. However, in the Auer 1989 study, dependence was considered to be Grade 5 according to its own scale. If there was more than one scale to evaluate the patients’ functional outcome within one article, we first selected the Barthel Index as the assessment scale, then the modified Rankin Scale and Glasgow Outcome Scale.

Statistical Analysis

The summary OR was used as the effect parameter for the meta-analysis, and the 95% CI was used to interpret the results. We assessed heterogeneity using the I² test and I². A probability value of ≥0.10 was taken as statistically significant, and an I² of 25%, 50%, and 75% represented low, moderate, and high heterogeneity, respectively. With low heterogeneity for outcome data, we used a fixed-effect model to analyze it. On the other hand, we used a random-effect model to analyze the pooled data with moderate or high heterogeneity. Considering the possibility that effectiveness may differ according to the surgical technique used, we conducted 2 subgroup analyses according to the type of MIS techniques and the type of other treatment options. We also conducted subgroup analysis regarding age, Glasgow Coma Scale (GCS) score, hematoma volume, and the timing of surgery. Inverted funnel plots and a regression test were used to assess the potential presence of publication bias. The protocol of the systematic review followed the recommendations for conducting a meta-analysis. We used Statistical Analysis System (Version 9.0; SAS Institute, Cary, NC) and RevMan5 software (Cochrane Information Management System) for all statistical analyses. All tests were 2-sided, and statistical significance was defined as a probability value of <0.05 if not specially stated otherwise.

Results

We initially retrieved 5602 potentially relevant studies. Of these, 3788 articles were excluded because the titles did not meet the inclusion criteria. One thousand one hundred fifty-six trials were removed by reviewing the abstracts. A total of 345 studies were excluded after 2 reviewers independently read the full texts (J.J.C., X.Y.Z.). Then 313 RCTs of included criteria were assessed the total score of study quality. Finally, a total score of <2 was the cutoff for study quality, which resulted in the exclusion of 301 studies. Thus, 12 trials of 1955 patients were considered to be eligible for inclusion in the meta-analysis (Figure 1).

In our study, there were 2 primary outcome data and one secondary outcome data available to incomplete data. In the Hosseini study, the authors did not evaluate the patients’ independence or dependence by any activities of daily living scales. Moreover, despite our best efforts such as by searching other related references, e-mail, and fax to all authors, we...
could not acquire the complete data of the Cho study and the Mendelow study.\textsuperscript{30,31}

In the MIS group, 8 trials involved stereotactic aspiration, 2 involved endoscopic surgery, and 2 involved both stereotactic aspiration and endoscopic surgery. In the other treatment group, 9 trials involved conservative medical treatment and 3 involved conventional craniotomy (Table 1). In addition, the main baseline characteristics, including age, hematoma location, hematoma volume, GCS score and timing of surgery, and the score of quality assessment of all trials, are shown in Table 2.

Data on death or dependence at final follow-up were available for 10 studies (Figure 2A). MIS was associated with a significant reduction in death or dependence at the end of follow-up. The value of OR was 0.54 (95% CI, 0.39–0.76). Statistically significant moderate heterogeneity was among the studies ($P=0.01, I^2=59\%$). However, after excluding the Mendelow study, there was statistically nonsignificant low heterogeneity ($P=0.12, I^2=38\%$), and the value of OR was 0.48 (95% CI, 0.36–0.63).

Data on death at final follow-up were available for 11 studies (Figure 2B). We found that MIS was associated with a statistically significant reduction in the OR of death at the end of follow-up. The value of OR was 0.53 (95% CI, 0.40–0.71). Heterogeneity among the studies was statistically nonsignificant low ($P=0.30, I^2=15\%$).

We conducted subgroup analyses based on the type of MIS: stereotactic aspiration or endoscopic surgery (Figure 3A), and the type of other treatment options: conservative medical treatment or conventional craniotomy (Figure 3B). Besides, we performed subgroup analysis regarding some main baseline characteristics, including age, GCS score, hematoma volume, and the timing of surgery (Figure 4).

In this review, 8 studies (66.7\%) were allocation concealment, and all studies reported incomplete outcome data or did intention-to-treat analysis. As far as we know, blinding is difficult in a surgical trial, but 5 studies (41.7\%) blinded the outcome assessment. Thus, all included studies in this review were consistently high quality. Moreover, we visually inspected the inverted funnel plots of these studies, which appeared to be approximately symmetrical. Because the total number of studies was too small to show clear asymmetry, we performed the Egger test and the results showed the primary outcome ($t=0.95, P=0.377$) and secondary outcome ($t=-0.26, P=0.805$) were not influenced by publication bias.

**Table 1. Design Characteristics of the Included Trials**

<table>
<thead>
<tr>
<th>Trials</th>
<th>MG</th>
<th>OG</th>
<th>Primary (MG:OG)</th>
<th>Secondary (MG:OG)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zhou 2011</td>
<td>Minimally invasive craniopuncture</td>
<td>Conventional craniotomy with large bone flap</td>
<td>12 mo BI (240/90:3878)</td>
<td>12 mo death (170/90:178)</td>
</tr>
<tr>
<td>Sun 2010</td>
<td>Minimally invasive craniopuncture</td>
<td>Conventional craniotomy with small bone flap</td>
<td>30 mo BI (90/159:93/145)</td>
<td>3 mo death (23/159:2314/145)</td>
</tr>
<tr>
<td>Wang 2009</td>
<td>Minimally invasive craniopuncture</td>
<td>Conservative medical treatment</td>
<td>3 mo BI (56/195:92/182)</td>
<td>3 mo death (13/195:16/182)</td>
</tr>
<tr>
<td>Kim 2009</td>
<td>Stereotactic aspiration</td>
<td>Conservative medical treatment</td>
<td>6 mo mRS (67/204:109/183)</td>
<td>6 mo death (11/204:17/183)</td>
</tr>
<tr>
<td>Miller 2008</td>
<td>Endoscopic surgery</td>
<td>Conservative medical treatment</td>
<td>3 mo mRS (6/6:4/4)</td>
<td>3 mo death (1/6:2/4)</td>
</tr>
<tr>
<td>Cho 2006</td>
<td>Endoscopic surgery plus Stereotactic aspiration</td>
<td>Conventional craniotomy</td>
<td>N</td>
<td>6 mo death (2/60:4/30)</td>
</tr>
<tr>
<td>Mendelow 2005</td>
<td>Endoscopic surgery plus Stereotactic aspiration</td>
<td>Conservative medical treatment</td>
<td>6 mo BI (51/69:58/86)</td>
<td>N</td>
</tr>
<tr>
<td>Hattoni 2004</td>
<td>Stereotactic aspiration</td>
<td>Conservative medical treatment</td>
<td>12 mo mRS (60/121:12/121)</td>
<td>12 mo death (9/121:20/121)</td>
</tr>
<tr>
<td>Teernstra 2003</td>
<td>Stereotactic aspiration</td>
<td>Conservative medical treatment</td>
<td>6 mo mRS (33/36:29/34)</td>
<td>6 mo death (20/36:20/34)</td>
</tr>
<tr>
<td>Zuccarello 1999</td>
<td>Stereotactic aspiration</td>
<td>Conservative medical treatment</td>
<td>3 mo BI (0/4:7/11)</td>
<td>3 mo death (0/4:3/11)</td>
</tr>
<tr>
<td>Auer 1989</td>
<td>Endoscopic surgery</td>
<td>Conservative medical treatment</td>
<td>6 mo outcome (28/50:37/50)</td>
<td>6 mo death (21/50:35/50)</td>
</tr>
</tbody>
</table>

MG indicates minimally invasive surgery; OG, other treatment options group; mo, months of follow-up; BI, Barthel Index (score of $\leq 60$ was viewed as dependent); mRS, modified Rankin Scale (score of $\geq 2$ was viewed as dependent); N, not available; m, months of follow-up.
Moreover, we excluded the low-quality RCTs with total indexed by international databases might have been missed. However, some studies published in journals that were not emphasize the role of MIS in the management of SICH.9 medical treatment, its evidence was not very robust and did not reported that the effectiveness of surgery was better than routine age, hematoma location, GCS score, hematoma volume, and the most likely candidates to benefit from MIS, including sex, patients with SICH. Moreover, we showed the characteristics of This review first reported that death and dependence of MIS important role of MIS in the management of SICH.33 imbalance. On the other hand, these numerous RCTs studies analysis of complete data, resulting in a potential risk of gross most from China, almost lacked truly randomization and incomplete data in the Mendelow study medical arm. Because this study was an international multicenter trial, the difference in surgical approach and conservative treatment in many countries with different medical levels may have led to potential heterogeneity.

In this review, MIS was associated with a 46% relative reduction in the OR of death or dependence and a 47% relative reduction in the OR of death. Although the control event rate is high, these relative risk reductions are still considerable. Furthermore, the relative risk reductions, which may better reflect the efficacy, were 21% for death or dependence and 36% for death. Both of them demonstrated that MIS has a significant benefit compared with other treatment options. In addition, we demonstrated that stereotactic aspiration was more effective in preventing death or dependence compared with endoscopic surgery, and conservative medical was more effective than conventional craniotomy in the death or dependence by subgroup analyses.

It is possible that the benefit is greater than that indicated because the 2 most important prognostic factors, hematoma volume and GCS score on admission, differed between the MIS group and the other treatment options group. The baseline in 6 trials showed that the hematoma volume of the MIS group was larger than that of the conservative medical group. The GCS of the MIS group in 4 trials was less than that in the conservative medical group. Although most of these imbalances were not significant in individual trials, the cumulative effect There was statistical heterogeneity for the primary outcome, whereas there was low heterogeneity for the secondary outcome. After a sensitivity analyses by excluding the Mendelow study, however, the primary outcome did not show significant heterogeneity ($P=0.12, F^2=38\%$) and there was no difference in the overall effect. A possible reason is that the inconsistency of the main baseline in this trial, resulting from a considerable number of patients in the MIS group, was deteriorating patients from the medical arm. Because this study was an international multicenter trial, the difference in surgical approach and conservative treatment in many countries with different medical levels may have led to potential heterogeneity.

Table 2. Characteristics of Patients and Quality Assessments of the Included Trials

<table>
<thead>
<tr>
<th>Trials</th>
<th>Age, y/Year</th>
<th>ICHL (MG/OG)</th>
<th>GCS Score (MG/OG)</th>
<th>ICHV/mL (MG/OG)</th>
<th>Timing of Surgery/h</th>
<th>Randomized Generation</th>
<th>Outcome Blinding</th>
<th>Incomplete Data</th>
<th>Allocation Concealment</th>
<th>Total Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zhou 2011\textsuperscript{10}</td>
<td>40–75</td>
<td>Basal ganglia; brain lobe</td>
<td>≥4 (8.1/8.4)</td>
<td>30–100 (—)</td>
<td>&lt;24</td>
<td>2</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td>Sun 2010\textsuperscript{22}</td>
<td>40–75</td>
<td>Basal ganglia</td>
<td>N</td>
<td>30–80 (52.3/21.7)</td>
<td>&lt;72</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>2</td>
<td>6</td>
</tr>
<tr>
<td>Wang 2009\textsuperscript{15}</td>
<td>40–75</td>
<td>Basal ganglia</td>
<td>≥9 (11.7/12.3)</td>
<td>25–40 (33.8/31.3)</td>
<td>&lt;72</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>2</td>
<td>7</td>
</tr>
<tr>
<td>Kim 2009\textsuperscript{11}</td>
<td>30–80</td>
<td>Basal ganglia; thalamus</td>
<td>≥13 (14.2/14.3)</td>
<td>&lt;30 (24.3/21.0)</td>
<td>&lt;120</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>Miller 2008\textsuperscript{21}</td>
<td>≥18</td>
<td>Supratentorial</td>
<td>≥4 (12/11)</td>
<td>&gt;15 (56.4/35.5)*</td>
<td>&lt;24</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Cho 2006\textsuperscript{30}</td>
<td>N</td>
<td>Basal ganglia</td>
<td>9 to 13 (9.68/9.32)</td>
<td>≥25 (43.8/42.1)</td>
<td>&lt;24</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Mendelow 2005\textsuperscript{31}</td>
<td>19–93</td>
<td>Supratentorial</td>
<td>≥5</td>
<td>Diameter &gt;2 cm</td>
<td>&lt;24</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>2</td>
<td>7</td>
</tr>
<tr>
<td>Hattori 2004\textsuperscript{42}</td>
<td>35–85</td>
<td>Putaminal</td>
<td>N</td>
<td>— (48/40)</td>
<td>&lt;24</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>2</td>
<td>7</td>
</tr>
<tr>
<td>Hesseini 2003\textsuperscript{39}</td>
<td>30–73</td>
<td>Supratentorial</td>
<td>N</td>
<td>40–120 (—)</td>
<td>&lt;24</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>4</td>
</tr>
<tr>
<td>Teernstra 2003\textsuperscript{43}</td>
<td>≥45</td>
<td>Supratentorial</td>
<td>≥4 (9.5/10)</td>
<td>&gt;10 (66/52)</td>
<td>&lt;72</td>
<td>2</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>5</td>
</tr>
<tr>
<td>Zuccarello 1999\textsuperscript{44}</td>
<td>&gt;18</td>
<td>Brain lobe; putaminal; thalamus; basal ganglia</td>
<td>≥4 (14.5/10.1)*</td>
<td>&gt;10 (29/38)</td>
<td>&lt;24</td>
<td>2</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>5</td>
</tr>
<tr>
<td>Auer 1989\textsuperscript{17}</td>
<td>30–80</td>
<td>Subcortical; putaminal; thalamus</td>
<td>N</td>
<td>&gt;10 (—)</td>
<td>&lt;48</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>2</td>
</tr>
</tbody>
</table>

*ICH indicates intracerebral hematoma location; MG, minimally invasive surgery group; OG, other treatment options group; GCS, Glasgow Coma Scale; ICHV, intracerebral hematoma volume; N, not mentioned; —, no significant difference.

**Discussion**

We have included almost all relevant RCTs in this review. However, some studies published in journals that were not indexed by international databases might have been missed. Fortunately, these studies are likely to be of low quality and would not significantly affect the results of this review. Moreover, we excluded the low-quality RCTs with total quality assessment score of <2. These excluded studies, mostly from China, almost lacked truly randomization and analysis of complete data, resulting in a potential risk of gross imbalance. On the other hand, these numerous RCTs studies reflected the severe challenges of Chinese clinicians and the important role of MIS in the management of SICH.33

In our study, the missing data of 2 articles would not significantly affect the results of this review. Although dependence data were lacked in the Cho study,\textsuperscript{30} the Barthel Index was significantly better in the endoscopic group (50.45±28.59) than in the craniotomy group (16.39±20.93; $P=0.006$), and mortality rates were significantly lower in the endoscopic group (3.3%) than in the craniotomy group (13.3%). Therefore, we have reason to speculate that the primary outcome in the Cho study was statistically lower in the endoscopic group than in the craniotomy group, which is consistent with the conclusion of this review. In addition, the incomplete data in the Mendelow study was only a secondary outcome, which would not significantly affect the result of this review.\textsuperscript{31}
might have been significant. So it is possible that an underesti-
mation of the benefit of MIS occurred. In addition, the manage-
ment of routine medical treatment may play a role in the benefit
of MIS. As we know, differences in this management exist in
individual trials depending on doctors’ experience and the quality of
medical service.35,36 Strictly speaking, excellent routine medical
treatment will improve the outcome of SICH treatment.

The most likely candidates to benefit from MIS are both
sexes, age of 30 to 80 years with superficial hematoma, GCS
score of \( \geq 9 \), hematoma volume between 25 and 40 mL, and
within 72 hours after onset of symptoms. We should emphasize
that these clinical characteristics of patients would not become
the limitation for MIS treatment in patients with SICH. Under
some circumstances, clinicians could be appropriate to expand
the indications according to the patient’s condition.

In our subgroup analysis, the patients who were aged \( \geq 18 \)
years had no statistical difference between MIS and other
treatment options, but the patients undergoing MIS aged \( \geq 30 \)
years had a significantly beneficial outcome. We consider
that the patients aged 18 to 30 years would recommend
having conservative medical treatment although there was a
lack of relative studies. Because most of included trials
limited the age to \( \leq 80 \) years, we suggest that the appropriate
age is 30 to 80 years. In this review, we ignore the issue of
MIS applying to the patients aged <18 years.

Patients with superficial hematoma are likely to benefit more
from endoscopic surgical removal. An early study demonstrated
that patients with subcortical hematomas benefited from endo-
sopic surgical removal by subgroup analysis, whereas those
with putaminal or thalamic hemorrhage did not.17 Another trial
showed that hematomas at a \( \leq 1 \) cm depth from the cortical
surface were more suitable for surgical treatment.31 Because of
a lack of enough evidence from subgroup analysis of hematoma
location, this potential benefit of hematoma location for SICH
needs more related studies for confirmation.

The impact of the GCS score on the benefit of MIS may be
closely related to the volume of SICH. With a GCS score of
\( \leq 4 \), the treatment choice in patients with SICH is largely
controversial.7,21 Cho et al reported that, with a GCS score of
4 to 12, the mortality rate of MIS was lower than that of
conservative treatment with the hematoma volume \( \geq 30 \) mL.
However, when the intracerebral hemorrhage volume was
\( \leq 30 \) mL, the mortality rates were the opposite.37 This study
supported our subgroup analysis result, which in the MIS
group would not be better than other treatment options with a
GCS score of \( \leq 4 \). Interestingly, with a GCS score of \( \geq 9 \), the
MIS group showed it to be significantly beneficial. In
additional, 2 studies have shown no difference in good
outcomes between conservative medical treatment and MIS.
in patients with a GCS score of 13 to 15. None of the studies included patients with GCS score of 4; therefore, whether surgery will benefit individuals who undergo surgery with a GCS score of 4 is still unknown.

Wide international variation exists in terms of what hematoma volume is suitable for MIS. The majority of scholars believed that surgical treatments, including MIS and craniotomy, are suitable for patients with SICH with a hematoma volume of 30 mL. In this subgroup analysis, MIS of hematoma volume ≥25 and ≤40 mL were both significantly better as far as primary outcome than other treatment options. Thus, we think the patients with hematoma volume between 25 and 40 mL would benefit most from MIS; however, because only few studies used this limit, the validity of this analysis is limited. Because there were wide controversies on this issue and its benefit would be influenced by other baseline characteristics.

Figure 3. Subgroup analyses: type of minimally invasive surgery (MIS) and other treatment options. Subgroup analyses according to: (A) type of MIS: endoscopic or stereotactic. B. Type of other treatment options: conservative medical or conventional craniotomy. MG indicates minimally invasive surgery group; OG, other treatment options group; CM, conservative medical; CC, conventional craniotomy.

### Table 1: Subgroup Analyses

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>MG Events</th>
<th>Total Events</th>
<th>Weight</th>
<th>Odds Ratio M-H, Fixed, 95% CI</th>
<th>Odds Ratio M-H, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>A</strong> stereotactic vs OG</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hatton 2004</td>
<td>60</td>
<td>121</td>
<td>121</td>
<td>15.1% 0.47 [0.28, 0.79]</td>
<td></td>
</tr>
<tr>
<td>Kim 2009</td>
<td>67</td>
<td>204</td>
<td>183</td>
<td>28.2% 0.33 [0.22, 0.50]</td>
<td></td>
</tr>
<tr>
<td>Sun 2010</td>
<td>90</td>
<td>159</td>
<td>145</td>
<td>15.4% 0.73 [0.46, 1.16]</td>
<td></td>
</tr>
<tr>
<td>Teernstra 2003</td>
<td>33</td>
<td>36</td>
<td>29</td>
<td>9.9% 1.90 [0.42, 8.64]</td>
<td></td>
</tr>
<tr>
<td>Wang 2009</td>
<td>56</td>
<td>195</td>
<td>182</td>
<td>22.1% 0.49 [0.32, 0.75]</td>
<td></td>
</tr>
<tr>
<td>Zhou 2011</td>
<td>24</td>
<td>90</td>
<td>38</td>
<td>10.9% 0.38 [0.20, 0.73]</td>
<td></td>
</tr>
<tr>
<td>Zuccarello 1999</td>
<td>0</td>
<td>4</td>
<td>7</td>
<td>1.5% 0.07 [0.00, 1.55]</td>
<td></td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>330</td>
<td>440</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| **B** endoscopic vs OG |           |              |        |                             |                             |
| Auer 1989          | 28        | 50           | 50     | 9.9% 0.45 [0.19, 1.04]       |                             |
| Miller 2006        | 6         | 6            | 4      | Not estimable               |                             |
| Subtotal (95% CI)  | 56        | 54           | 54     | 9.9% 0.45 [0.19, 1.04]       |                             |

| **C** total events | 364       | 481          |        |                             |                             |

| **Figure 3** | Subgroup analyses: type of minimally invasive surgery (MIS) and other treatment options. Subgroup analyses according to: (A) type of MIS: endoscopic or stereotactic. B. Type of other treatment options: conservative medical or conventional craniotomy. MG indicates minimally invasive surgery group; OG, other treatment options group; CM, conservative medical; CC, conventional craniotomy.
the hematoma volume could not become only one standard to
triage patients for MIS or other treatment options.38 Some clinical studies have reported a classification of the
surgery timing, that is from the onset of symptoms to the time
of operation, ranging from within 24 hours (ultraearly stage),
within 24 to 72 hours (early stage), and up to 72 hours
(deferred stage).39,40 In our study, ultraearly surgery might be
more beneficial for patients with SICH. However, this seems
not to be better in earlier surgery. A small, single-center
randomized study showed that the rebleeding rate of craniot-
omy within 4 hours of symptom onset was higher than that
within 12 hours.41 In this review, the patients undergoing MIS
within 72 hours would significantly improve the primary
outcome compared with other treatment options.42–44 Because
only one small study was involved in deferred staged surgery,
we could not demonstrate whether patients will benefit from
MIS beyond 72 hours of onset.

Summary
This meta-analysis first provides powerful evidence from
high-quality RCTs that the effectiveness of MIS was signif-
iciently better than those of other treatment options, including

the hematoma volume could not become only one standard to
triage patients for MIS or other treatment options.38

Some clinical studies have reported a classification of the
surgery timing, that is from the onset of symptoms to the time
of operation, ranging from within 24 hours (ultraearly stage),
within 24 to 72 hours (early stage), and up to 72 hours
(deferred stage).39,40 In our study, ultraearly surgery might be
more beneficial for patients with SICH. However, this seems
not to be better in earlier surgery. A small, single-center
randomized study showed that the rebleeding rate of craniot-
omy within 4 hours of symptom onset was higher than that
within 12 hours.41 In this review, the patients undergoing MIS
within 72 hours would significantly improve the primary
outcome compared with other treatment options.42–44 Because
only one small study was involved in deferred staged surgery,
we could not demonstrate whether patients will benefit from
MIS beyond 72 hours of onset.

Summary
This meta-analysis first provides powerful evidence from
high-quality RCTs that the effectiveness of MIS was signif-
ificant better than those of other treatment options, including
craniotherapy and conservative treatment. Furthermore, we
described the characteristics of the most likely candidates to
benefit from MIS. Above all, this review would guide
clinicians to judge treatment options and appropriate patients
for minimally invasive surgery in SICH. Promisingly, some
recruiting studies (Surgical Trial in Lobar Intracerebral Hem-
orrhage [STICH] II, Minimally Invasive [stereotactic] Sur-
gery Plus rtPA for ICH Evaluation [MISTIE]) have been in
progress and these results may strengthen our conclusion.45

Acknowledgments
We thank Houguang Zhou from Fudan University, Huashan Hospi-
tal, Department of Neurology, Shanghai, China, and Wenzhi Wang
from the National Office for Cerebrovascular Diseases (CVD)
Prevention and Control in China, Beijing, China, for additional
(unpublished) information on studies of MIS for SICH. We also
thank Qing Liu from School of Public Health, Chongqing Medical
University, for guide the methods of this review.

Disclosures
None.
References
Minimally Invasive Surgery for Spontaneous Supratentorial Intracerebral Hemorrhage: A Meta-Analysis of Randomized Controlled Trials
Xinyu Zhou, Jianjun Chen, Qi Li, Gaoping Ren, Guoen Yao, Ming Liu, Qiang Dong, Jing Guo, Leilei Li, Jing Guo and Peng Xie

Stroke. published online September 18, 2012;
Stroke is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2012 American Heart Association, Inc. All rights reserved.
Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://stroke.ahajournals.org/content/early/2012/09/18/STROKEAHA.112.667535

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Stroke can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Stroke is online at:
http://stroke.ahajournals.org//subscriptions/